BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates
BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.88 per share a year ago.
BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore
BridgeBio remains a compelling Buy, driven by Attruby's strong U.S. launch and favorable competitive dynamics following Pfizer's patent settlements. Attruby's peak annual sales are conservatively modeled at $2.2B, with sensitivity up to $4B, underpinned by a protected branded market through mid-2031. BBIO's late-stage pipeline—infigratinib, encaleret, and BBP-418—offers potential for additional blockbusters, supporting long-term value beyond Attruby.
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cinctive Capital Management LP Sells 98,688 Shares of BridgeBio Pharma, Inc. $BBIO
Cinctive Capital Management LP trimmed its stake in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 50.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 95,672 shares of the company's stock after selling 98,688 shares during the quarter. Cinctive
BridgeBio Pharma, Inc. (BBIO) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
BridgeBio Pharma, Inc. (BBIO) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
BridgeBio Pharma (BBIO) Reports Q4 Loss, Beats Revenue Estimates
BridgeBio Pharma (BBIO) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to a loss of $1.31 per share a year ago.
BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript
BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript
BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript
BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript
BridgeBio Pharma shares rise on ‘compelling' Phase 3 trial results for achondroplasia drug
BridgeBio Pharma (NASDAQ:BBIO) saw its shares rise more than 5% to about $77 on Thursday after reporting positive Phase 3 topline results for oral infigratinib in achondroplasia, with Jefferies analysts describing the data as “compelling.” Achondroplasia is the most common form of dwarfism, a genetic condition that affects bone growth and results in short stature and disproportionate limb development.
BridgeBio Pharma (BBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Buy the Dip on This Biotech Stock After Recent Fall
BridgeBio Pharma Inc (NASDAQ:BBIO) stock pulled back sharply from its Jan. 22 record high of $81.33, marking a three-month low after Pfizer withdrew a tafamidis patent in the European Union (EU).
BridgeBio Pharma (BBIO) Surges 6.8%: Is This an Indication of Further Gains?
BridgeBio Pharma (BBIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
